Streetbeat News

Regulatory

EVGO

EVgo Inc. has received a conditional commitment for a $1.05 billion loan guarantee from the U.S. Department of Energy to expand its fast charging network across the U.S. This financing will support the construction of approximately 7,500 new DC fast charging stalls.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:41 pm

GRRR

Gorilla Technology Group Inc. (NASDAQ:GRRR) is actively combating market manipulation of its stock and plans to repurchase more shares under its buyback program, indicating confidence in its undervalued stock.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:21 pm

PCRX

Pacira BioSciences announced that the Centers for Medicare and Medicaid Services has issued a new J-code for EXPAREL, effective January 1, 2025. This change is expected to streamline billing and reimbursement processes.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:12 pm

BABA

JD

NIO

XPEV

US-listed Chinese stocks are experiencing a decline after a recent rally spurred by a new stimulus package from the People's Bank of China. The pullback comes as the sector adjusts following the initial boost.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:06 pm

IMMP

Immutep Limited has completed patient enrollment for the Phase II AIPAC-003 trial, testing eftilagimod alpha with paclitaxel in metastatic breast cancer patients. The trial aims to determine the optimal biological dose, aligning with FDA's Project Optimus.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:04 pm

OSTX

OS Therapies has completed a Phase 2b clinical trial for OST-HER2 in recurred osteosarcoma and is preparing to request an FDA Type C meeting. The company expects data analysis and topline results in Q4 2024. OS Therapies will ring the NYSE closing bell today, and CEO Paul Romness will appear on Fintech.TV and Schwab Network.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:03 pm

TOVX

Theriva Biologics announced a positive review from the Data and Safety Monitoring Committee for its Phase 1b/2a trial of SYN-004 in preventing acute graft-versus-host-disease in transplant recipients. The study will proceed to enroll Cohort 3.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 12:03 pm

T

TMUS

VZ

European telecom companies, including Vodafone, Telefonica, and Orange, are considering legal action against SpaceX's Starlink if the FCC relaxes radio emission rules. They argue that such changes could harm terrestrial mobile networks. U.S. companies like AT&T and Verizon also express concerns. SpaceX seeks a waiver to ensure reliable communications, especially during emergencies, and has reached a milestone with its 7,000th satellite launch.

Portfolio Pulse from Rounak Jain

October 03, 2024 | 11:50 am

PIRS

Palvella Therapeutics, the merger partner of Pieris Pharmaceuticals, has received a grant of up to $2.6 million from the FDA's Office of Orphan Products Development. This grant will support the Phase 3 SELVA trial of QTORIN 3.9% Rapamycin Anhydrous Gel for treating Microcystic Lymphatic Malformations.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:42 am

ELAB

Elevai Labs has filed two patent applications for its lead candidate, EL-22, targeting muscle loss treatment in obese patients. The patents cover standalone and combination therapies with GLP-1 receptor agonists.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:38 am